A β-lapachone β-glucuronideprodrug would take advantageof not only the target specificity imparted by NQO1 and 5-LO overexpressionin PDAC, but also the tumor-specific activation given by the expressionof β-glucuronidase. The gene discussed is NQO1; the disease is neoplasm.